Fairmount Funds Management LLC
Annual return
—
SPY
—
Alpha
—
Invested
$2.8B
Holdings
12
Trades YTD
0
Performance · Fund vs SPY
Cumulative return · quarterly snapshotsIn development
Quarterly performance not yet computed for this fund.
The metrics pipeline computes return / SPY benchmark / alpha per quarter from this fund's 13F holdings and the SPY adj-close. It hasn't produced enough quarters here yet — the chart fills in automatically once at least two are on record.
Top holdings · current snapshot
Source: 13F-HR
Carry-forward filing.
Latest filing (2026-03-31) contained only unmappable securities. Holdings shown are carried forward from Q4 2025.
01
$DMRA
DAMORA THERAPEUTICS INC
Held since at least Q1 2024
16.6%
02
$DNTH
DIANTHUS THERAPEUTICS INC
Q3 2025: Increased +22.2% (2.71M → 3.31M shares)
15.7%
03
$COGT
COGENT BIOSCIENCES INC
Q3 2025: Increased +44.6% (6.23M → 9.00M shares)
15.6%
04
$SYRE
SPYRE THERAPEUTICS INC
Q4 2024: New position (4.02M shares)
14.9%
05
$ORKA
ORUKA THERAPEUTICS INC
Q3 2025: Increased +9.9% (3.37M → 3.71M shares)
13.4%
06
$VRDN
VIRIDIAN THERAPEUTICS INC
Q4 2024: New position (3.45M shares)
5.6%
07
$ELVN
ENLIVEN THERAPEUTICS INC
Q2 2025: Increased +15.9% (3.20M → 3.71M shares)
5.4%
08
$JBIO
JADE BIOSCIENCES INC
Q2 2025: New position (3.22M shares)
4.7%
09
$ZBIO
ZENAS BIOPHARMA INC
Q4 2024: New position (1.89M shares)
3.4%
10
$CBIO
CRESCENT BIOPHARMA INC.
Q2 2025: New position (1.39M shares)
1.9%
Recent trades · Last 90 days
No Form 4 / 13D / 13G trade events on file in the recent window. 13F filers report position snapshots quarterly rather than per-trade events, so this section is most useful for managers who also file Form 4 or 13D/G.
Source data: SEC EDGAR · 13F-HR filings · Last refreshed 08:30 UTC.